april
well
sustain
suscept
infect
rapid
accur
diagnost
assay
essenti
detect
novel
influenza
variant
among
molecular
diagnost
method
develop
date
tandem
monoplex
assay
target
either
differ
region
singl
viral
gene
segment
differ
viral
gene
segment
describ
dualgen
duplex
quantit
realtim
rtpcr
method
select
target
pandem
influenza
assay
design
includ
primerprob
set
specif
hemag
silico
analysi
specif
ha
oligonucleotid
sequenc
use
assay
show
target
swineorigin
pandem
strain
also
crossreact
wide
spectrum
noninfluenza
respiratori
virus
assay
diagnost
sensit
specif
respect
lower
detect
limit
viral
gene
copi
pcr
adapt
either
qualit
quantit
mode
first
appli
patient
influenzalik
ill
tertiari
hospit
singapor
contain
phase
pandem
sinc
first
case
pandem
influenza
viru
swineorigin
appear
mexico
april
variou
diagnost
assay
realtim
convent
revers
transcriptionpolymeras
chain
reaction
assay
rtpcr
antigen
test
luminex
xtag
respiratori
viral
panel
direct
immunofluoresc
test
rmix
viral
cultur
includ
emerg
use
author
assay
center
diseas
control
prevent
cdc
cdc
protocol
realtim
rtpcr
rrtpcr
swine
influenza
http
wwwwhointcsrresourc
pdf
last
access
april
develop
provid
accur
rapid
detect
novel
viru
allow
time
treatment
infect
control
measur
taken
limit
spread
viru
date
realtim
rtpcr
diagnost
method
describ
elsewher
either
monoplex
assay
tandem
monoplex
assay
target
differ
region
singl
gene
segment
eg
hemagglutinin
matrix
protein
tandem
monoplex
assay
target
differ
viral
gene
segment
provid
costand
laboreffect
diagnost
servic
possibl
second
wave
viru
includ
abil
close
monitor
viral
load
patient
influenza
gene
mutant
lead
drug
resist
dualgen
quantit
realtim
rtpcr
qrtpcr
assay
target
rel
variabl
hemagglutinin
ha
envelop
protein
gene
conserv
intern
nucleoprotein
np
gene
would
select
detect
pandem
influenza
viru
develop
singletub
format
first
develop
optim
qualit
assay
rrtpcr
rapid
detect
infect
later
date
adapt
quantit
test
qrtpcr
enabl
viral
load
measur
discuss
clinic
perform
assay
valid
enhanc
surveil
contain
period
may
juli
larg
teach
hospit
singapor
nation
univers
hospit
nuh
relat
primari
care
clinic
use
assay
protocol
patient
sampl
approv
institut
review
board
midmay
nation
healthcar
group
dsrb
nasopharyng
nasal
throat
swab
cerebrospin
fluid
sputum
collect
symptomat
patient
contact
present
nuh
affili
primari
care
clinic
includ
patient
attend
outpati
clinic
emerg
medicin
depart
nuh
public
privat
primari
care
clinic
inpati
influenzalik
symptom
well
patient
staff
compat
contact
travel
histori
surveil
program
swab
kept
ml
univers
transport
medium
copan
diagnost
inc
corona
ca
viral
rna
extract
l
univers
transport
medium
either
qiagen
viru
mini
kit
qiasymphoni
virusbacteria
mini
kit
use
respect
proprietari
bio
robot
qiasymphoni
autom
platform
qiagen
valencia
ca
accord
manufactur
instruct
drygel
swab
swab
preprocess
l
l
use
extract
describ
cerebrospin
fluid
specimen
l
cerebrospin
fluid
directli
use
extract
sputum
specimen
l
sputum
resuspend
l
nacetylcystein
rna
extract
l
suspens
sampl
type
extract
viral
rna
elut
final
volum
l
elut
buffer
use
publish
sequenc
ha
segment
np
segment
refer
design
primer
taqman
probe
combin
assay
figur
ad
confirm
target
specif
ha
primerprob
combin
check
ha
gene
sequenc
nonpandem
swineorigin
influenza
strain
obtain
ncbi
influenza
viru
resourc
silico
see
supplement
figur
http
jmdamjpatholorg
script
quantifi
use
nanodrop
uvvi
spectrophotomet
nanodrop
technolog
wilmington
de
absorpt
wavelength
nm
serial
dilut
rnasefre
water
copi
per
l
lower
detect
limit
determin
quantit
standard
curv
analysi
onestep
rrtpcr
amplif
perform
use
superscript
iii
platinum
onestep
qrtpcr
reagent
invitrogen
carlsbad
ca
lightcycl
system
roch
molecular
diagnost
pleasanton
ca
lightcycl
use
colorcompens
fam
hex
fluoresc
signal
gener
duplex
assay
accord
manufactur
protocol
minim
cross
talk
differ
channel
real
time
pcr
instrument
reaction
volum
contain
l
extract
rna
templat
l
superscript
iii
rtplatinum
taq
mix
l
reaction
mix
moll
np
forward
primer
moll
np
revers
primer
moll
np
probe
moll
ha
forward
primer
moll
ha
revers
primer
moll
ha
probe
primer
probe
obtain
eurogentec
ait
sera
belgium
cycl
condit
includ
initi
revers
transcript
minut
denatur
minut
step
follow
cycl
amplif
data
acquisit
stage
fluoresc
signal
detect
cycl
np
ha
amplif
curv
analyz
absorpt
wavelength
nm
nm
respect
posit
defin
ct
crossoverthreshold
cycl
cycl
gene
target
appropri
posit
control
neg
nontempl
control
includ
everi
test
run
forward
underlin
nucleotid
repres
modif
made
spackman
et
al
analyt
specif
dualgen
assay
first
test
panel
archiv
respiratori
virus
isol
patient
sampl
includ
season
influenza
influenza
b
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
coronavirus
human
metapneumoviru
verifi
noncross
reactiv
virus
use
part
influenza
diagnost
strategi
alongsid
univers
influenza
rna
extract
sampl
screen
influenza
virus
human
avian
swine
origin
influenza
b
viru
pandem
influenza
simultan
sampl
detect
influenza
test
neg
pandem
strain
season
influenza
subtyp
rrtpcr
assay
human
virus
ensu
four
screen
subtyp
assay
use
diagnost
suit
previous
publish
literatur
optim
conform
laboratori
set
eg
instrumentplatform
avail
small
import
modif
made
spackman
univers
influenza
assay
inclus
addit
revers
primer
enhanc
detect
swineorigin
influenza
viru
tabl
cdc
emerg
use
author
assay
run
parallel
first
influenza
posit
sampl
initi
clinic
valid
inhous
assay
rrtpcr
describ
adapt
quantif
viral
load
infect
patient
pcr
amplif
effici
lower
detect
limit
qrtpcr
assay
determin
sevenpoint
standard
curv
construct
amplif
duplic
serial
dilut
rna
transcript
control
contain
viral
gene
copi
per
pcr
pcr
effici
valu
calcul
formula
e
slope
standard
curv
describ
kinet
pcr
amplif
indic
quickli
amount
target
nucleic
acid
expect
increas
amplif
cycl
relat
effici
amplif
reaction
determin
interassay
reproduc
replic
sixpoint
serial
dilut
np
ha
rna
transcript
copi
per
pcr
prepar
equival
copi
number
np
ha
gene
segment
analyz
consecut
batch
run
two
differ
oper
adequ
valid
qrtpcr
use
measur
viral
load
clinic
specimen
two
separ
occas
two
differ
oper
determin
reproduc
qrtpcr
assay
clinic
specimen
patient
specimen
analyz
repres
full
rang
possibl
viral
load
concentr
obtain
patient
cohort
contain
period
may
juli
repeat
test
done
thaw
aliquot
kept
immedi
diagnost
test
singl
freezethaw
cycl
statist
analysi
perform
use
spss
sta
none
archiv
noninfluenza
respiratori
virus
test
show
crossreact
highli
specif
ha
primerprob
set
assay
also
crossreact
ha
gene
nonpandem
swine
influenza
subtyp
analyz
insilico
also
crossreact
observ
np
primerprob
set
panel
noninfluenza
virus
test
period
heighten
surveil
may
juli
patient
influenzalik
symptom
test
use
dualgen
assay
alongsid
univers
influenza
univers
influenza
b
screen
assay
season
influenza
subtyp
assay
influenza
b
season
influenza
season
influenza
case
viru
infect
see
tabl
first
posit
case
detect
dualgen
duplex
assay
gave
concord
cdc
method
assay
appear
highli
specif
pandem
influenza
variant
presenc
season
influenza
viru
b
subtypesnon
sampl
show
posit
either
season
influenza
influenza
b
gave
posit
result
dualgen
assay
howev
six
haonli
nponli
posit
result
total
case
found
patient
shown
infect
pandem
influenza
strain
sister
laboratori
use
anoth
laboratorydevelop
method
unpublish
data
case
found
patient
postantivir
treatment
followup
low
viral
titer
detect
threshold
cycl
viru
detect
probabl
becam
stochast
later
stage
viral
shed
scenario
aros
would
repeat
assay
event
repeat
consist
discrep
use
backup
assay
cdc
eua
assay
provid
correct
result
hand
dualgen
duplex
assay
clinic
valid
sensit
specif
base
case
posit
infect
influenza
rapid
turnaround
time
hour
sampl
receipt
result
output
figur
b
show
standard
amplif
curv
np
ha
rna
transcript
duplic
lower
limit
detect
np
ha
target
defin
lowest
dilut
reproduc
amplif
copi
per
pcr
pcr
effici
np
gene
target
ha
gene
boxplot
drawn
use
amplif
curv
threshold
cycl
ct
valu
npand
haseri
dilut
rna
transcript
control
six
point
gene
perform
separ
run
shown
figur
b
percentag
coeffici
variat
cv
sd
control
level
deriv
assess
interassay
imprecis
gave
overal
cv
sd
six
point
best
fit
line
confid
interv
calcul
mean
drawn
use
ct
valu
consecut
separ
run
show
r
valu
np
ha
figur
c
differ
first
second
ct
valu
read
obtain
duplic
test
clinic
specimen
best
fit
line
np
figur
ha
figur
gene
target
scatter
plot
ct
valu
initi
diagnost
test
repeat
test
archiv
specimen
deriv
np
plot
ha
plot
r
r
respect
figur
b
find
signific
differ
subset
sampl
perform
duplic
test
patient
sampl
rna
store
previou
extract
rna
reextract
vtm
duplic
test
thereaft
use
store
rna
remain
data
collect
store
excess
rna
extract
eluent
buffer
freezer
suitabl
aliquot
usag
hand
store
rna
remain
intact
month
inhous
dualgen
rrtpcr
assay
target
region
ha
gene
segment
could
reliabl
discrimin
influenza
viru
influenza
strain
human
swine
influenza
b
ha
gene
known
rel
high
mutat
rate
may
caus
primerprob
mismatch
subsequ
loss
assay
sensit
second
region
conserv
intern
np
gene
also
target
design
dualgen
assay
region
target
np
gene
common
swineorigin
influenza
increas
specif
confirm
assay
influenza
human
season
influenza
assay
demonstr
optimum
pcr
effici
specimen
perform
two
separ
run
sever
day
apart
show
major
ct
valu
initi
versu
repeat
test
well
correl
r
np
ha
substanti
high
reproduc
rnabas
assay
clinic
specimen
wide
rang
viral
load
expect
infect
patient
differ
duplic
patient
expect
good
duplic
analys
plasmid
transfect
attribut
like
presenc
inher
contamin
former
could
act
potenti
inhibitor
pcr
amplif
often
refer
matrix
effect
northern
hemispher
enter
annual
season
influenza
period
winter
month
presenc
pandem
strain
may
increas
morbid
mortal
usual
level
region
world
health
organ
prepar
second
wave
lesson
current
outbreak
http
wwwwhointcsrdiseaseswineflu
last
access
august
unlik
previou
pandem
influenza
virus
displac
previou
season
influenza
strain
becom
current
predomin
circul
strain
appear
recent
sporad
resurg
season
influenza
b
virus
certain
part
world
health
organ
pandem
updat
http
wwwwhointcsrdon
last
access
juli
howev
given
continu
global
circul
reliabl
diagnost
assay
still
requir
screen
novel
influenza
subtyp
rapidli
accur
addit
quantit
capabl
assay
viral
load
measur
enabl
better
monitor
drugresist
influenza
mutat
begin
evolv
infect
patient
posttreat
eg
oseltamivir
resist
influenza
probabl
humantohuman
transmiss
first
report
novemb
recent
studi
describ
natur
viral
load
profil
pandem
viru
report
reduct
rate
log
copiesmlday
post
symptom
onset
patient
receiv
oseltamivir
within
two
day
symptom
onset
versu
log
copiesmlday
receiv
treatment
viral
load
undetect
day
oseltamivir
treatment
observ
persist
high
viral
load
clinic
suspici
oseltamivirtr
patient
would
suggest
presenc
drugresist
mutant
may
warrant
identif
studi
context
dualgen
duplex
rrtpcr
assay
qualit
quantit
mode
offer
robust
sensit
specif
option
detect
quantit
viral
load
determin
influenza
variant
